Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

CUP

- PMLiVE

Five myths about emerging markets

From strategy to access and beyond, a new look at pharma's fast-growing markets

- PMLiVE

Consultation begins on new patient access scheme

EMA hopes PRIME will improve development of prioritymedicines and ease access concerns

- PMLiVE

Choosing wisely

How to make the best of emerging markets

- PMLiVE

Guido Rasi set for return as EMA executive director

Regulator's board nominates him to resume hisleadership role

- PMLiVE

National Audit Office agrees CDF is ‘unsustainable’

Says a replacement for the CDF is urgently needed

- PMLiVE

Orphan drug firm Sobi opens new European base

Company'sBrussels office will also house its Benelux operations

- PMLiVE

Taking a strategic approach

Janssen's Cyril Titeux on responding to the industry's pricing, access and reputational challenges

- PMLiVE

FDA grants Tocagen’s glioblastoma drug orphan status

Puts the brain cancer gene therapy in-line for development incentives

- PMLiVE

Oncology directions

With increasingly expensive cancer drugs, what price should be paid for innovation?

- PMLiVE

Critical thinking

Assessing the Darwinian model of mutation in pharmaceutical companies

- PMLiVE

Dr June Raine continues as chair of EMA’s pharmacovigilance committee

The PRAC also voted to extend Dr Almath Spooner's tenure asvice-chair

- PMLiVE

Pharma must ‘create new social contract’

New task force established in UK to assess public’s view of the value and risk of medicines

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links